To The Moon

$UnitedHealth(UNH)$ 

Analysis: Berkshire’s Move & Is $300 a Good Entry Point?

1. What's Behind the Move

Berkshire Hathaway, through its recently filed Q2 2025 13F, revealed that it initiated a new position in UnitedHealth, acquiring approximately 5.04 million shares worth about $1.57 billion, at an average price near $314/share.

UnitedHealth stock jumped 10–14% on this news, buoyed by what’s often referred to as the “Buffett Bounce.”

Multiple reputable sources describe this as a strategic contrarian move, with Berkshire leaning into healthcare amid broader turbulence and sector underperformance.

---

2. Should You Follow at $300?

Reasons It Could Make Sense

Valuation anchoring: At around $304, the current price is slightly below Berkshire’s average cost (~$314)—potentially offering a modest price advantage.

Contrarian endorsement: Buffett likely views this as a long-term opportunity, signaling confidence amid UNH’s recent downturn and regulatory headwinds.

Sector rebound potential: Healthcare, and particularly UnitedHealth, may benefit from an improved outlook if regulatory pressures ease or management stabilizes.

Risks to Consider

Operational challenges persist: UnitedHealth faces serious issues—DOJ investigations into Medicare Advantage billing, rising costs, CEO turnover, and a cyberattack.

Earnings under pressure: The company missed earnings forecasts two quarters in a row and had to withdraw its 2025 guidance. Even the reinstated outlook remains conservative.

Analyst caution: Some analysts expect continued headwinds for the next 18 months, suggesting any recovery may be gradual.

Buffett’s price discipline: Buying at $314 suggests the forward-looking potential is there—but $300 doesn’t represent a significant discount, especially given the risks.

---

3. What Could Be a Smarter Entry Strategy

Dollar-cost averaging: Rather than jumping in at $300, consider a phased approach, building a position incrementally—especially if volatility continues.

Wait for stabilization: A retracement into the low-to-mid $290s, perhaps triggered by regulatory update or earnings, could offer a more compelling entry point.

Set clear risk parameters: If you initiate a position, consider setting stop-loss orders or defining targets—Buffett typically emphasizes margin of safety.

---

Summary Table

Question Insight

Why did Buffett buy? Long-term contrarian stake amid UNH’s recent underperformance and threats

Is $300 a buy? Plausible, but not a strong discount—proceed cautiously and thoughtfully

Best entry strategy? Gradual accumulation, particularly if price dips or volatility returns

Risks? Regulatory/legal issues, cost pressures, leadership instability, guidance uncertainty

---

Disclaimer: This is an informational analysis as of August 16, 2025, and does not constitute investment advice. Please consider your own risk tolerance, objectives, and consult a financial advisor as needed.